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Abstract
Background: Exposure to noxious gases and particles contained in both tobacco smoking (TS) and biomass smoke
(BS) are well recognized environmental risk factors for chronic obstructive pulmonary disease (COPD). COPD is
characterized by an abnormal inflammatory response, both in the pulmonary and systemic compartments. The
differential effects of TS, BS or their combined exposure have not been well characterized yet. This study sought to
compare the lung function characteristics and systemic inflammatory response in COPD patients exposed to TS, BS
or their combination.
Methods: Sociodemographic, clinical and lung functional parameters were compared across 49 COPD patients with
a history of smoking and no BS exposure (TS COPD), 31 never-smoker COPD patients with BS exposure (BS COPD),
46 COPD patients with a combined exposure (TS + BS COPD) and 52 healthy controls (HC) who have never been
exposed neither to TS or BS. Blood cell counts, C-reactive protein (CRP), fibrinogen and immunoglobulin E (IgE)
levels were quantified in all four groups.
Results: TS + BS COPD patients exhibited significantly lower oxygen saturation than the rest of groups (p < 0.01).
Spirometry and diffusing capacity were significantly higher in BS than in TS or TS + BS patients. CRP levels were
significantly higher in TS COPD patients than in BS COPD group (p < 0.05), whereas fibrinogen was raised in COPD
patients with a history of smoking (TS and TS + BS) when compared to control subjects (p < 0.01). Finally, COPD
patients with BS exposure (BS and BS + TS groups) showed higher IgE levels than TS and HC (p < 0.05).
Conclusions: There are significant physiological and inflammatory differences between COPD patients with TS, BS
and TS + BS exposures. The latter had worse blood oxygenation, whereas the raised levels of IgE in BS exposed
patients suggests a differential Th2 systemic inflammatory pattern triggered by this pollutant.
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Background
COPD is characterized by an abnormal response of the
lungs to toxic particles and gases, resulting in a progres-
sive and not fully reversible airway obstruction whose
main pathologic hallmarks are bronchiolitis and lung
parenchymal emphysematous destruction [1]. Despite
tobacco smoke (TS) is the environmental risk factor most
frequently and clearly associated to COPD, exposure to
biomass smoke (BS) has also been proposed as one of the
main risk factors for developing the disease, especially
among non-smokers [2, 3]. In this respect, the existing
evidence of clinical, functional, radiologic and histopatho-
logic differences between TS and BS-exposed COPD pa-
tients has raised the hypothesis of two distinct phenotypes
of COPD, according to the main triggering risk factor.
Thus, in addition to the known gender difference on ex-
posure chance, BS COPD patients exhibit a milder airflow
obstruction –measured by FEV1 and FEV1/FVC– than TS
COPD subjects, as well as a higher DLCO values [4–7]. On
the other hand, BS COPD patients show more anthracosis
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and pulmonary fibrosis and less emphysema than TS
COPD patients [8–10].
The evidence of different pathologic features in COPD
patients exposed to BS or TS underpin the existence of a
third potential phenotype which remains largely unchar-
acterized: COPD patients with a significant exposure to
both TS and BS (TS + BS COPD). Given the toxicity of
both kinds of smoke, a higher severity of pulmonary
damage could be expected in double-exposed subjects.
Following this line of thought, Dogan et al. [11] com-
pared lung histopathological alterations among rats
exposed exclusively to TS, those exclusively exposed to
BS and a group with combined exposure to TS and BS.
They found an increased severity in perivascular inflam-
mation, as well as higher parenchymal infiltration, num-
ber of alveolar macrophages and vascular wall thickness
in lungs of rats exposed to both BS and TS than in those
only exposed to BS [11]. In turn, with data from the
PREPOCOL study [12], Torres-Duque et al. [13] com-
pared some demographical and functional parameters
among 114 COPD patients exposed to wood smoke, 81
COPD patients exposed to TS and 264 COPD patients
exposed to both types of smoke, reporting significant de-
creases in FEV1 and FEV1/FVC values in patients with a
combined exposure [13]. In both studies, the authors
suggested that a combined exposure to TS and BS could
have a noxious additive effect in COPD patients and
could increase the frequency of COPD symptoms.
On another front, although COPD is primarily a
disease of the lungs and airways, it also has several
extra-pulmonary manifestations and comorbidities.
Indeed, systemic inflammation is a hallmark of COPD
and it may be involved in cardiovascular complications
in COPD patients [14]. Accordingly, increased numbers
of inflammatory cells have been reported not only in
small airways and lung parenchyma of COPD patients
[15–17], but also in peripheral blood [18, 19]. Moreover,
several molecular inflammatory markers are also in-
creased in blood of COPD patients. One of the most
widely studied is C-reactive protein (CRP), an acute-
phase reactant secreted by the liver during inflammatory
processes, which is increased in both stable and exacer-
bated COPD patients [20]. This biomarker has also
proved to predict mortality outcomes in subjects with
COPD [21]. COPD patients show higher blood levels of
other inflammatory markers, such as interleukine (IL)-6,
IL-8, tumor necrosis factor (TNF)-α and fibrinogen
when compared to control subjects [22, 23]. Regarding
the last one, it has been shown that fibrinogen is associ-
ated with disease severity and can also predict risk of
exacerbations and mortality in COPD patients, thus
highlighting its importance in predicting clinical out-
comes [24, 25]. Notwithstanding, the role of other
classical biomarkers of inflammation in COPD remain
elusive. This is case of immunoglobulin E (IgE), which is
mostly associated with asthma-COPD overlap syndrome
(ACOS) [26], although it has also been shown to be
increased in non-atopic COPD patients [27]. In spite of
the importance of systemic inflammatory biomarkers in the
understanding of COPD, data on systemic inflammation
profile in BS COPD is scarce and no study has assessed
these biomarkers in TS + BS COPD patients so far.
The purpose of the present study is to elucidate
whether there are differences in clinical, functional and




We studied 126 COPD patients and 52 healthy volunteers
recruited at Hospital Regional de Talca, Talca, Chile. The
Ethics Committees of Maulean Health Service and
Universidad Autónoma de Chile approved the study and
written informed consent was obtained from all the
subjects.
COPD patients were recruited at the Respiratory
Service of the Hospital, where they attended to undergo
diagnostic tests after suspected COPD or for COPD
monitoring visits. Control subjects were recruited in par-
allel at the same ward through a volunteer recruitment
program. After clinical characterization and risk factors
assessment, subjects were classified into four groups: 49
TS COPD patients (ex-smokers with no BS exposure),
31 BS COPD patients (never-smokers with BS exposure),
46 TS + BS COPD patients (subjects with a combined
exposure to TS and BS) and 52 controls, consisting in
subjects with no record of any specific illness and with
neither smoking history nor biomass smoke exposure.
Diagnostic evaluation of subjects was conducted
according to GOLD criteria [1] and medical history was
considered standardizing clinical information. Standard
procedures [28] and equipment (Masterlab; Jaeger,
Würzburg, Germany) were used to assess pulmonary
function in all patients, including measurements of
forced expiratory volume in 1 s (FEV1), forced vital cap-
acity (FVC) and carbon monoxide diffusing capacity of
the lung (DLCO). Oxygen saturation was measured in all
patients by pulse-oximetry (Ohmeda TuffSat, Soma
Technology, Connecticut, USA). Body mass index (BMI)
was calculated using the current weight and the tallest
height of each study participant. Dyspnea was deter-
mined using the modified Medical Research Council
scale (mMRC) and exercise capacity was determined
with the distance walked in 6 min test (6MWT). Health-
related quality of life and symptom burden in patients
with COPD was quantified using the COPD assessment
test (CAT). A Body-mass, airflow Obstruction, Dyspnea
and Exercise (BODE) score was assigned to each COPD
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patient. Subjects were excluded from the study when
they presented a history of asthma, rhinitis or any extra-
pulmonary disease affecting lung function, and when
they had a positive bronchodilator test, FEV1 increasing
by ≥12% and 200 ml. In order to ensure that COPD
patients were stable, those with a COPD exacerbation or
hospitalization record during the previous two months
were also excluded from the study.
Risk factors
Risk factors for COPD were considered to be exposure
to either BS or TS as determined by the clinical
interview and a standardized Spanish version of the
CanCOLD study questionnaire [29] with the addition of
some questions referring to biomass fuels.
For BS exposure assessment, specifically, subjects were
asked the following two questions: 1) Has an indoor
open fire with coal, coke, wood, pellet, agricultural resi-
due or animal dung been used in your home as a pri-
mary means of cooking or heating for more than
6 months in your life? 2) For how many years? Subjects
who answered affirmatively to first question and 9 or
more years to the second question were considered as
BS exposed. Cumulative exposure to biomass smoke was
calculated and expressed as hour-years as previously
described [4]. The amount of cigarette smoking history
was measured by pack-years.
Systemic inflammatory markers
A Beckman Coulter LH 750 analyzer (Beckman Coulter
Inc., California, USA) was used to assess the blood cell
counts. Serum CRP and IgE levels were measured by
immunoturbidimetry and electrochemiluminescence im-
munoassay, respectively, using a Cobas 6000 analyzer
(Roche Diagnostics, Basel, Switzerland). Plasma fibrino-
gen was measured by the Clauss method using the STA-
Fibrinogen reagent and the STA-R evolution coagulation
analyzer (Roche Diagnostics, Basel, Switzerland).
Statistical analysis
Data are expressed as mean ± standard deviation or
median (range) according to whether they conform to
normal distribution. Differences among groups were
analyzed using the analysis of variance (ANOVA) for
parametric data (demographic, clinical and biomarkers
data) and the Kruskall-Wallis test for non-parametric
data (blood cell counts). When differences in cell counts
were significant, the Kruskal-Wallis test was followed by
the Mann-Whitney U test for comparison between
groups. Correlations were calculated by Spearman’s rank
correlation test. Significance level was set at p < 0.05. All
analyses were performed using R statistical pack (R
Foundation for Statistical Computing, Vienna, Austria).
Results
Demographic and clinical findings
Table 1 presents the main clinical and functional charac-
teristics of study subjects. The Chi-square test revealed
significant differences in gender proportions between
control subjects and smoking COPD groups (TS and
TS + BS) as well as between TS COPD and BS COPD
(p < 0.05). The four groups had similar age. TS and
BS exposures were similar in TS COPD and TS + BS
COPD and BS COPD and TS + BS COPD, respect-
ively. HS completed a significantly higher number of
schooling years as compared to COPD patients. Fur-
thermore, TS COPD patients showed a significantly
higher average of schooling years when compared to
BS-exposed groups. HC also had a significantly higher
BMI value than COPD patients. There were no sig-
nificant differences in the number of exacerbations in
the previous year among COPD groups.
Lung function
COPD patients had a significantly reduced FEV1 and
FEV1/FVC than HC. These parameters were significantly
higher in BS than TS or double-exposed patients (Table
1). Likewise, BS COPD patients also showed a higher
DLCO than other COPD groups. Interestingly, oxygen
saturation was significantly reduced in TS + BS COPD
patients when compared to the rest of groups (p < 0.01).
Finally, no differences among COPD groups were found
in 6 MW test, mMRC, CAT and BODE index.
Systemic inflammatory markers
In order to determine whether the systemic inflamma-
tory response was different among TS, BS and TS + BS
COPD patients, blood levels of CRP, fibrinogen and
immunoglobulin E were assessed (Fig. 1).
TS COPD patients showed a significantly higher level
of CRP than BS COPD patients and control subjects
(7.56 ± 2.68 vs 3.42 ± 1.90 and 1.79 ± 1.10 mg/l, respect-
ively) (p < 0.05, Fig. 1a). Blood levels of fibrinogen were
significantly increased in TS and TS + BS COPD patients
when compared to control subjects (392.22 ± 106.38 and
378.85 ± 84.27 vs 319.81 ± 70.52 mg/dl) (p < 0.01, Fig. 1b).
However, no significant differences in this biomarker were
found between BS COPD and control subjects. Import-
antly, total IgE levels were significantly increased in BS
and TB + BS COPD groups (492.87 ± 127.89 and 454.19 ±
140.69 UI/ml, respectively) as compared to TB COPD pa-
tients and control subjects (81.23 ± 50.34 and 60.57 ±
33.76 UI/ml, respectively) (p < 0.05, Fig. 1c).
On the other hand, there were no significant differ-
ences in erythrocytes, platelets and basophils among
COPD groups (Table 2). However, COPD patients had
higher numbers of neutrophils and lymphocytes than
control subjects (p < 0.01). Furthermore, total leucocyte
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and monocyte counts were significantly higher in COPD
patients with a history of smoking than in BS COPD
and control subjects (p < 0.05 and p < 0.01, respect-
ively, Table 2). Finally, the neutrophil-to-lymphocyte
ratio (NLR) was significantly higher in COPD patients
than control subjects (p < 0.01).
Correlations of interest
Some significant correlations between clinical and haem-
atological parameters were found when all COPD
patients were considered as one group. An inverse
correlation was found between this CRP and FEV1 (% of
predicted) (R = −0.19, p < 0.05). FEV1 was also inversely
correlated with total leucocyte counts (R = −0.19, p < 0.05),
as well as with neutrophils (R = −0.24, p < 0.05) and mono-
cytes (R = −0.27, p < 0.01) counts. Moreover, exercise
capacity was inversely correlated with fibrinogen and IgE
(R = −0.59, p < 0.01 and R = −0.63, p < 0.01, respectively) as
well as with eosinophils (R = −0.47, p < 0.05). Regarding
BODE index, it was significantly correlated with fibrinogen
(R = 0.59, p < 0.01) and IgE (R = 0.53, p < 0.05).
With respect to exposure to risk factors, significant
correlations were found between pack-years and eo-
sinophils (R = 0.30, p < 0.05) and neutrophils (R = 0.27,
p < 0.05) counts, as well as with NLR ratio (R = 0.26,
p < 0.05). Moreover, the cumulative exposure to
biomass smoke was significantly correlated with total
blood leucocytes (R = 0.69, p < 0.01), neutrophils (R =
0.78, p < 0.01) and lymphocytes (R = 0.55, p < 0.05)
counts, in addition to NLR ratio (R = 0.52, p < 0.05).
Finally, no significant correlation was found between
tobacco pack-years or biomass cumulative exposure
and lung function parameters.
Discussion
The results of this study show that there are significant
clinical, functional and systemic differences between
COPD patients exposed to TS, BS or both. In general,
lung function was more severely impaired in COPD
patients exposed to TS, who also showed higher levels of
fibrinogen, circulating leucocytes and monocytes,
whereas COPD patients exposed to BS had significantly
higher levels of blood IgE. These results suggest different
inflammatory responses to different inhaled pollutants in
COPD.
Previous studies
To our knowledge, this is the first article comparing
clinical, functional and blood parameters among TS
COPD patients, BS COPD patients, COPD patients
exposed to both risk factors and healthy subjects never
exposed to either of them.
A previous study presented at the American Thoracic
Society 2013 International Conference by Torres-Duque
et al. [13], however, compared the effects of the com-
bined exposure to TS and wood smoke in lung function
of COPD patients. They reported significant decreases in
FEV1 and FEV1/FVC values in patients with a combined
Table 1 Demographic and clinical data
Control Subjectsn = 52 TS COPDn = 49 BS COPDn = 31 TS + BS COPD n = 46
Sex, Male (%)/Female (%) 15(29)/37(71) 35(71)/14(29) 12(39)/19(61) 26(63)/20(37)
Age, years 70.34 ± 5.95 69.41 ± 8.69 72.29 ± 9.49 69.93 ± 7.19
Smoking history, pack-years – 41.57 ± 25.62 – 55.46 ± 47.12
Biomass exposure, hour-years – – 340.90 ± 206.09 345.15 ± 193.16
Scolarship, years 13.21 ± 2.06 7.56 ± 4.25a 5.20 ± 3.59a, b 6.09 ± 3.93a, b
BMI, kg/m2 30.09 ± 5.54 27.67 ± 5.08a 26.57 ± 3.06a 27.35 ± 5.69a
Exacerbations in the previous year – 1.10 ± 1.37 0.58 ± 0.42 0.69 ± 1.29
FEV1, % predicted 110.19 ± 17.46 56.88 ± 19.37
a, c 68.09 ± 32.30a 53.79 ± 18.67a, c
FEV1/FVC, % predicted 103.87 ± 8.13 67.75 ± 14.00
a,c 74.16 ± 10.69a 67.56 ± 15.97a, c
DLCO, % predicted 81.52 ± 21.21 66.60 ± 19.82
a 73.73 ± 17.16 61.22 ± 24.98a, c
Oxygen Saturation, % 96.91 ± 1.36 92.65 ± 4.55a 93.94 ± 4.04a 90.52 ± 4.90a, b, c
6 MW, meters 492.48 ± 78.51 355.96 ± 163.02a 375.29 ± 143.75a 344.09 ± 161.12a
mMRC – 2.38 ± 1.47 2.37 ± 1.16 2.67 ± 1.03
CAT – 15.49 ± 8.21 14.84 ± 6.69 13.18 ± 6.69
BODE – 2.88 ± 5.71 2.71 ± 6.35 3.87 ± 7.72
Data presented as mean ± standard deviation, unless otherwise indicated. Definition of abbreviations: BMI body-mass index, FEV1 forced expiratory volume in 1 s,
FVC forced vital capacity. DLCO carbon monoxide diffusing capacity, 6 MW 6 min walking test, mMRC modified Medical Research Council scale CAT COPD
assessment test, BODE Body-mass, airflow Obstruction, Dyspnea and Exercise index
aDifferent from control subjects (p < 0.05, by ANOVA)
bDifferent from TS COPD (p < 0.05, by ANOVA)
cDifferent from BS COPD (p < 0.05, by ANOVA)
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exposure. Conversely, we found that FEV1 and FEV1/
FVC values were similar between TS and TS + BS COPD
group and significantly lower than in BS group. Since no
data about amount of exposure to TS and BS was
available in the study of Torres-Duque et al. [13], the
differences in the double exposed group may be due to a
higher exposure to TS and/or BS in these patients than
in those with a single exposure. Moreover, the contra-
dictory results between the study of Torres-Duque et al.
and the present one could also be explained by the fact
that they only considered wood smoke exposure,
whereas we considered different sources of BS.
Interpretation of findings
Despite the Global Burden of Disease study reported 1.1
million COPD-related deaths for tobacco smoking and
850.000 to indoor pollution in 2010 [30], information
about the characteristics of COPD patients with a com-
bined exposure to both risk factors is virtually non-
existent. The following novel observations emerge from
our study:
First, although it is well established that lower socio-
economic status and education level is associated with
COPD [31–33], we observed that the number of years of
scholarship was significantly reduced in BS COPD and
TS + BS COPD patients when compared to TS COPD
patients. This is likely related to the fact that the use of
biomass as a source of energy is more widespread in
rural areas, where also the access to education is more
difficult, especially some decades ago.
Second, arterial oxygen saturation was significantly
lower in double exposed COPD patients, suggesting an in-
creased ventilation/perfusion mismatch in these patients
[34]. Bearing in mind that that both smoking [35] and ex-
posure to some components of BS [36] have been related
to a decrease in oxygen saturation, this result likely re-
flects an additive effect of both exposures, and it has im-
portant clinical implications, since an oxygen saturation
cut-off value of ≤92% is considered when screening for re-
spiratory failure in patients with COPD [37]. In spite of
this, no other functional parameter was exclusively im-
paired in the TS + BS COPD group, albeit airflow limita-
tion was more severe in TS COPD than in BS COPD
patients, in keeping with some previous studies [4, 5, 7].
Third, CRP levels were significantly higher in TS than
in BS COPD and HS. This contrasts with two previous
studies reporting similar CRP levels in TS and wood-
smoke exposed COPD patients [38, 39]. This discrep-
ancy may be explained by the different techniques used
in CRP quantification (ELISA and immunoturbidimetry)
and the characteristics of the study populations. It’s
worth to mention, however, that both in our study and
in one of these previous ones [38] CRP levels were in-
versely related with FEV1 values, as it has been reported
in other TS COPD studies [40, 41]. Likewise, circulating
levels of fibrinogen were also significantly higher in TS
and TS + BS COPD patients than in HC, in keeping with
some previous studies also reporting higher levels of
fibrinogen in smokers [42, 43].
Fig. 1 Quantification of systemic inflammatory markers. a) CRP levels, b)
Fibrinogen levels, c) Ig E levels. αDifferent from control subjects (p< 0.05).
βDifferent from TS COPD group (p< 0.05). χDifferent from BS COPD
group (p < 0.05)
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Fourth, circulating IgE levels were significantly higher
in COPD groups with a BS exposure (BS and TS + BS)
than in TS COPD and HC. Although it has been shown
that particulate matter (PM) and polycyclic aromatic hy-
drocarbons (PAHs) contained in BS increase blood IgE
levels [44–46], this is the first study reporting an in-
crease of this inflammatory marker specifically in COPD
patients exposed to BS. Since an increase of IgE produc-
tion represents a typical feature of a Th2 response, this
result suggests that BS could trigger a specific inflamma-
tory Th2 response in COPD patients. In fact, Solleiro-
Villavicencio et al. reported a higher frequency of Th2
cells and a higher concentration of IL-2 in blood of BS
vs. TS COPD patients and HC [47]. Although quantifica-
tion of lymphocyte subsets was not available in our
study, it is noteworthy that cumulative BS was signifi-
cantly correlated with total blood lymphocyte counts.
On the other hand, the increased IgE levels observed in
BS COPD patients could also underlie the higher preva-
lence of ACOS reported in COPD subjects exposed to
BS [7]. Moreover, the transversal nature of the present
study does not allow ruling out the possibility of other
exposures capable of raising Ig E levels, particularly in
rural areas.
Of note, a previous study comparing IgE and fibrino-
gen between COPD patients exposed to TS and BS [39]
reported similar blood levels of both biomarkers in both
groups. We believe that this discrepancy can be ex-
plained by sample size, ethnic and sex differences [48]
(75% of males in the cited study vs. 58% of males in the
present one). Moreover, since the composition of BS
depends on the type of fuel and the combustion condi-
tions, BS exposure from different sources may lead to
different clinical features.
Finally, our results showed significantly increased
numbers of neutrophils, lymphocytes and NLR in all
COPD groups vs. HC. This highlights a general a
systemic inflammatory process mounted in response to
the inhalation of noxious gases and particles in COPD,
regardless of their specific type.
Potential limitations
The present study has several potential limitations.
Firstly, the study population was relatively small.
However, we believe that the rigorous characterization
of subjects allowed establishing reliable comparisons
among groups. Secondly, imaging and histopathological
analyses which would have allowed the assessment of
small airways thickening and emphysema were not avail-
able. Thirdly, patterns of exposure to BS and TS may
have biased our results, since COPD patients with a
smoking history were actually ex-smokers, whereas
several BS exposed subjects reported a current use of
biomass fuels. Fourthly, although subjects with a history
of asthma and/or reversibility in post-bronchodilator
FEV1 were excluded from our study, we cannot rule out
the possibility of ACOS among our patients, since no uni-
fied definition or diagnostic criteria for ACOS exists. Fi-
nally, given that subjects exposed to BS exhibited a lower
socioeconomic status and an ancestry characterization
was not available, both environmental and genetic vari-
ables may have been a potential source of bias.
Conclusions
There is a synergistic damaging effect of the combined
exposure to TB and BS. The systemic inflammatory re-
sponse in these two types of COPD is, however, distinct.
Given that BS and TS have many components in com-
mon, a further characterization at a molecular level
would be necessary in order to elucidate which ones
could be responsible of different inflammatory features,
and in which concentrations.
Table 2 Blood cell counts
Control Subjectsn = 52 TS COPDn = 49 BS COPDn = 31 TS + BS COPD n = 46
Eritrocytes, 1 × 106 μl 4.53 (3.11–5.51) 4.64 (3.49–5.83) 4.54 (3.65–6.04) 4.79 (3.92–5.88)
Platelets, 1 × 103 μl 251.00 (142.00–477.00) 251.00 (118.00–553.00) 243.00 (132.00–389.00) 236.00 (144.00–360.00)
Leucocytes, 1 × 103 μl 7.40 (3.50–10.80) 8.80 (4.10–12.60)a, c 7.90 (4.10–11.70) 8.20 (5.30–11.80)a, c
Neutrophils, 1 × 103 μl 4.20 (2.00–7.00) 5.60 (2.50–8.10)a 5.20 (2.20–7.80)a 4.90 (2.80–7.50)a
Eosinophils, 1 × 102 μl 0.20 (0.00–0.30) 0.20 (0.00–0.30) 0.10 (0.00–0.60) 0.20 (0.00–0.70)
Basophils, 1 × 10 μl 0.50 (0.00–2.20) 0.40 (0.00–1.20) 0.50 (0.00–1.00) 0.50 (0.00–1.00)
Monocytes, 1 × 103 μl 0.50 (0.20–0.70) 0.60 (0.40–6.00)a, c 0.50 (0.30–1.10) 0.60 (0.40–1.60)a, c
Lymphocytes, 1 × 103 μl 2.38 (1.20–3.90) 2.06 (0.80–3.80)a 1.76 (1.00–2.80)a 2.11 (1.00–3.60)a
NLR 1.76 (0.87–3.00) 2.46 (1.36–5.14)a 2.94 (1.09–6.10)a 2.48 (0.88–4.18)a
Data presented as median (range). NLR: neutrophil-to-lymphocyte ratio
aDifferent from control subjects (p < 0.05, by Kruskall-Wallis test)
bDifferent from TS COPD (p < 0.05, by Kruskall-Wallis test)
dDifferent from BS COPD (p < 0.05, by Kruskall-Wallis test)
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